drugset
drugset / Trial / NCT05130177

Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma

NCT05130177 ↗

Phase 2 Active not recruiting 8 enrolled Diwakar Davar Arcus Biosciences, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The main goal of this study is to establish the proportion of patients with objective response to zimberelimab/domvanalimab in PD-1 R/R melanoma patients.

Timeline

Start
2022-03-16
Primary completion
2026-02-06
Completion
2030-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Domvanalimab Monoclonal antibody 15 mg/kg Intravenous
Subject Zimberelimab Monoclonal antibody 360 mg Intravenous

Indications

melanoma